Mechanism Of Action:
Dapagliflozin inhibits the sodium-glucose contransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose resorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.
Indication:
- Dapagliflozin is indicated to be used as monotherapy or in combination with insulin or other antidiabetic medicines in adult patients with type 2 diabetes mellitus.
- For reducing the risk of cardiovascular death and hospitalization in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
- For reducing the risk of cardiovascular death and hospitalization in adult patients with heart failure with reduced ejection fraction.
- Dapagliflozin can also be used for reducing the risk of end-stage kidney disease (ESKD) and hospitalization or death from heart problems in adult patients who also have kidney problems caused by type 2 diabetes.
